# CSTC1 for Diabetic Foot Ulcers Phase II Study

> **NCT01813305** · PHASE2 · COMPLETED · sponsor: **Charsire Biotechnology Corp.** · enrollment: 124 (actual)

## Conditions studied

- Diabetic Foot Ulcer
- Diabetes Mellitus
- Wounds

## Interventions

- **DRUG:** CSTC1
- **DRUG:** CSTC1 Matched vehicle

## Key facts

- **NCT ID:** NCT01813305
- **Lead sponsor:** Charsire Biotechnology Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-09
- **Primary completion:** 2020-01-07
- **Final completion:** 2020-01-07
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2022-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813305, "CSTC1 for Diabetic Foot Ulcers Phase II Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01813305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*